Obermatt
See Similar Stocks →

Flags

Financial distress

Myriad Genetics

NSQ:MYGN · US62855J1043
BiotechnologyMedium

360

12
Profit price23
Owner Earnings Yield1
Dividend Yield1
Price/Sales95
EV / Gross Profit85
Price/Book70
Return on Capital76
Cash Return on Capital28
Return on Equity26
EBIT Margin55
Gross Profitability94
Accruals97
Owner Earnings Margin60
Sales growth41
Profit growth58
Reinvestment49
Price momentum38
Debt load46
Refinancing92
Debt Payback1
Liquidity29
Analyst ratings10
Opinion Changes23
Price Target Upside11
Market mood35
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Myriad Genetics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1992
Employees2,273
Websitemyriad.com
ISINUS62855J1043
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsPsychiatryFertilityGeneticsGenetic DisorderOncologyBiotechnologyPharmaceutical

Description

Myriad Genetics, Inc. operates as a molecular diagnostic testing and precision medicine company. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company's tests assess the risk o…

Analysis

Middle-of-the-road

Myriad Genetics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is fragile. The company scores 4/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
24
2026

All-time high

68

Mar 2026

All-time low

24

Jun 2026

Average rank

46

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
95
—
—
—
Price/Earnings
10
—
—
—
Price/Book
70
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
60
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Myriad Genetics with its peers
Natera
NSQ:NTRA
39
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Rigel Pharmaceuticals
NSQ:RIGL
66
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
National Research
NSQ:NRC
43
CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
LifeStance Health
NSQ:LFST
80
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kestra Medical Technologies
NSQ:KMTS
21
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →